Expression data from second oncogene expressing Melanoma Cells.

Among the myriad tumors analyzed to date, cutaneous malignant melanomas bear some of the highest mutational burdens. Thus, it is somewhat surprising that oncogene exclusion between is so pronounced in melanomas where there is only a single melanoma out of 366 sequenced specimens which harbors concurrent BRAF(V600E/M) and NRAS(G13R) mutations (TCGA-ES-A2NC Sample; WWW.bioportal.org), In this senario some NRAS and BRAF mutations co-expressing cells show slow growth phenotypes by under study mechanism. We used Affymetrix GeneChip Expression Arrays to detail the global programme of gene expression underlying oncogenic exclusion and identified distinct classes of up and down-regulated genes during this process. Total mRNA was collected at 5th day from doxycycline induced and non-induced melanoma cell lines (A375(BRAF*)+iNRAS*, GMEL(BRAF*)+iNRAS*,SKMEL119(NRAS*)+iBRAF*) to express second oncogene respectively and subjected for hybridization on Affymetrix microarrays.